Metabolic bone disease in children: Etiology and treatment options

Treatments in Endocrinology

Volumn 5, Issue 5, 2006, Pages 297-318

  Skowrońska Jóźwiak, Elzbieta ^a   Lorenc, Roman S ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CARBAMAZEPINE; CINACALCET; CORTICOSTEROID; CYCLOSPORIN; DOXERCALCIFEROL; ESTROGEN DERIVATIVE; HUMAN GROWTH HORMONE; METHOTREXATE; OSTEOPROTEGERIN; OXYGENASE; PARATHYROID HORMONE; PARICALCITOL; PHENOBARBITAL; PHENYTOIN; PHOSPHATE; PRIMIDONE; RECOMBINANT SOMATOMEDIN C; STRONTIUM RANELATE; TESTOSTERONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALPROIC ACID; VITAMIN D; CALCIUM INTAKE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOSOMAL DOMINANT DISORDER; BONE DISEASE; BONE DYSPLASIA; BONE MALFORMATION; BONE MARROW TRANSPLANTATION; BONE METASTASIS; BONE PAIN; BONE REMODELING; CHILD; CHONDRODYSPLASIA; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG METABOLISM; ENDOCRINE DISEASE; ENZYME DEFICIENCY; EXERCISE; FAMILIAL DISEASE; FIBROUS DYSPLASIA; GASTROINTESTINAL DISEASE; GENE THERAPY; GENETIC DISORDER; HUMAN; HYPERCALCIURIA; HYPOPHOSPHATASIA; HYPOPHOSPHATEMIA; JUVENILE OSTEOPOROSIS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; LIVER TRANSPLANTATION; MALABSORPTION; MALIGNANT NEOPLASTIC DISEASE; METAPHYSIS; MOTOR DYSFUNCTION; NEUROMUSCULAR DISEASE; NORRIE DISEASE; NUTRITIONAL DEFICIENCY; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PAGET BONE DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSEUDOHYPOPARATHYROIDISM; RENAL OSTEODYSTROPHY; REVIEW; RICKETS; SECONDARY OSTEOPOROSIS; X CHROMOSOME LINKED DISORDER; ADMINISTRATION AND DOSAGE; BONE DEVELOPMENT; CALCIUM INTAKE; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FRACTURE; METABOLIC BONE DISEASE; PROSPECTIVE STUDY; VITAMIN D DEFICIENCY;

BONE DEVELOPMENT; BONE DISEASES, METABOLIC; CALCIUM, DIETARY; CHILD; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FRACTURES, BONE; HUMANS; PROSPECTIVE STUDIES; RENAL OSTEODYSTROPHY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 33749348940     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605050-00004     Document Type: Review

References (221)

1. Saggese G, Baroncelli GI, Bertelloni S. Osteoporosis in children and adolescents: diagnosis, risk factors, and prevention. J Pediatr Endocrinol Metab 2001; 12: 833-59
2. Key LL, Ries WL. Slerosing bone dysplasia. In: Glorieux FH, Pettifor JM, Juppner H, editors. Pediatric bone. Amsterdam: Academic Press, 2003
3. Pettifor JM. Nutritional rickets. In: Glorieux FH, Pettifor JM, Juppner H, editors. Pediatric bone: biology and diseases. Amsterdam: Academic Press, 2003: 541-66
4. Schoenau E, Rauch F. Assessment of bone metabolism and biochemical markers. In: Ranke MB, editor. Diagnostics of endocrine function in children and adolescents. Basel: Karger, 2003: 460-70
5. Chan YY, Bishop NJ. Clinical management of childhood osteoporosis. Int J Clin Pract 2002; 56: 280-6
6. Cassidy JT. Osteopenia and osteoporosis in children. Clin Exp Rheumatol 1999; 17: 245-50
7. The Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom 2004; 7: 17-26
8. Adams JE. Bone mass measurement in children: DXA: pros and cons [abstract]. Bone 2005; 36 Suppl. 1: S12
9. Bonjour JP, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73: 555-63
10. Jaworski M, Lebiedowski M, Lorenc RS, et al. Ultrasound bone measurement in pediatric subjects. Calcif Tissue Int 1995; 56: 368-71
11. Schalamon J, Singer G, Schwantzer G, et al. Quantitative ultrasound assessment in children with fractures. J Bone Miner Res 2004; 19: 1276-9
12. Marowska J, Kobylinska M, Lukaszkiewicz J, et al. Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents: normal values and clinical application. Bone 1996; 19: 669-77
13. Lorenc RS. Idiopathic juvenile osteoporosis. Calcif Tissue Int 2002; 70: 395-7
14. Antoniazzi F, Mottes M, Fraschini P, et al. Osteogenesis imperfecta practical treatment guidelines. Pediatr Drugs 2000; 2: 465-88
15. Sillence DO. Osteogenesis imperfecta nosology and genetics. Ann N Y Acad Sci 1988; 543: 1-15
16. Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000; 15: 1650-8
17. Glorieux FH, Ward LM, Rauch F, et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002; 17: 30-8
18. Labuda M, Morissette J, Ward LM, et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 2002; 31: 19-25
19. Shaw DG, Hall CM, Carty H. Osteogenesis imperfecta: the distinction from child abuse and the recognition of a variant form. Am J Med Genet 1995; 13: 116-8
20. Eastell R. Role of oestrogen in the regulation of bone turnover at the menarche. J Endocrinol 2005; 185: 223-34
21. Veldhuis JD, Roemmich JN, Richmond EJ, et al. Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev 2005; 26: 114-46
22. Grinspoon S, Thomas E, Pitts S, et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med 2000; 133: 790-4
23. Biller BMK, Saxe V, Herzog DB, et al. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J Clin Endocrinol Metab 1989; 68: 548-54
24. Di Somma C, Pivonello R, Loche S, et al. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf) 2003; 58: 302-8
25. Scommegna S, Greening JP, Storr HL, et al. Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease. J Endocrinol Invest 2005; 28: 231-5
26. Compston J. Glucocorticoid-induced osteoporosis. Horm Res 2003; 60 Suppl. 3: 77-9
27. Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005; 94: 15-21
28. Yeap SS, Hosking DJ. Management of glucocosteroid-induced osteoporosis. Rheumatology (Oxford) 2002; 41: 1088-94
29. Mora S, Weber G, Marenzi K, et al. Longitudinal changes of bone density and bone resorption in hyperthyroid girls during treatment. J Bone Miner Res 1999; 14: 1971-7
30. Lucidarme N, Ruiz JC, Czernichow P, et al. Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves' disease. J Pediatr 2000; 137: 56-62
31. Radetti G, Bona G, Corrias A, et al. Does Graves' disease during puberty influence adult bone mineral density? Horm Res 2002; 58: 176-9
32. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994; 130: 350-6
33. Kollars J, Zarroug AE, van Heerden J, et al. Primary hyperparathyroidism in pediatric patients. Pediatrics 2005; 115 (4): 974-80
34. Consensus Development Conference Panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med 1991; 114: 593-7
35. De Schepper J, Smitz J, Rosseneu S, et al. Lumbar spine bone mineral density in diabetic children with recent onset. Horm Res 1998; 50: 193-6
36. Duntas LH. Prolactinomas in children and adolescents: consequences in adult life. J Pediatr Endocrinol Metab 2001; 14 Suppl. 5: 1227-32
37. Baroncelli GI, Bertelloni S, Ceccarelli C, et al. Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency. J Clin Endocrinol Metab 1998; 83: 3150-4
38. Bouillon R, Koledova E, Bezlepkina O, et al. Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 2004; 89: 4993-8
39. Lee JJK, Lyne ED. Pathologic fractures in severely handicapped children and young adults. J Pediatr Orthop 1990; 10: 497-500
40. Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med 2004 Feb; 71 Suppl. 2: S42-8
41. Tolman KG, Jubiz W, Sannella JJ, et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 1975; 56: 45-51
42. Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002; 58 (9): 1348-53
43. Sheth RD. Bone health in pediatric epilepsy. Epilepsy Behav 2004; 5 Suppl. 2: S30-5
44. Harpavat M, Keljo DJ. Perspectives on osteoporosis in pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2003; 5 (3): 225-32
45. Sylvester FA. IBD and skeletal health: children are not small adults! Inflamm Bowel Dis 2005; 11: 1020-3
46. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 2004; 126: 1550-60
47. O'Leary C, Wieneke P, Healy M, et al. Celiac disease and the transition from childhood to adulthood: a 28-year follow-up. Am J Gastroenterol 2004; 99: 2437-41
48. Smith C, Hubbard R. Fracture risk in people with celiac disease: a population-based cohort study. Gastroenterology 2003; 125: 429-36
49. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002; 156: 1-10
50. Mora S, Barera G, Ricotti A, et al. Reversal of low bone density with a gluten-free diet in children and adolescents with celiac disease. Am J Clin Nutr 1998; 67: 477-81
51. Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40: 1-19
52. Isaia G, Di Stefano M, Roggia C, et al. Bone disorders in cholestatic liver diseases. Forum (Genova) 1998; 8: 28-38
53. Floreani A, Mega A, Camozzi V, et al. Is osteoporosis a peculiar association with primary biliary cirrhosis? World J Gastroenterol 2005; 11: 5347-50
54. Pawlowska J, Matusik H, Socha P, et al. Beneficial effect of liver transplantation on bone mineral density in small infants with cholestasis. Transplant Proc 2004; 36: 1479-80
55. Cimaz R. Osteoporosis in childhood rheumatic diseases: prevention and therapy. Best Pract Res Clin Rheumatol 2002; 16: 397-409
56. Lien G, Selvaag AM, Flato B, et al. A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 833-40
57. Henderson CJ, Cawkwell GD, Specker BL, et al. Predictors of total body bone mineral density in non-corticosteroid-treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 97; 40: 1967-75
58. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000; 43: 1960-6
59. Rudge S, Hailwood S, Horne A, et al. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 2005; 44: 813-8
60. Pagano-Therrien J, Santacroce SJ. Bone mineral density decrements and children diagnosed with cancer. J Pediatr Oncol Nurs 2005; 22 (6): 328-38
61. Arikoski P, Komulainen J, Riikonen P, et al. Reduced bone density at completion of chemotherapy for a malignancy. Arch Dis Child 1999; 80: 143-8
62. Annapoorna N, Venkateswara Rao G, Reddy NS, et al. An increased risk of osteoporosis during acquired immunodeficiency syndrome. Int J Med Sci 2004; 1: 152-64
63. Thomas J, Doherty SM. HIV infection: a risk factor for osteoporosis. J Acquir Immune Defic Syndr 2003; 33: 281-91
64. Feber J, Cochat P, Braillon P, et al. Bone mineral density after renal transplantation in children. J Pediatr 1994; 125: 870-5
65. Acott PD, Crocker JF, Wong JA. Decreased bone mineral density in the pediatric renal transplant population. Pediatr Transplant 2003; 7: 358-63
66. Wharton B, Bishop N. Rickets. Lancet 2003; 362: 1389-400
67. Sills IN, Skuza KA, Horlick MN, et al. Vitamin D deficiency rickets: reports of its demise are exaggerated. Clin Pediatr (Phila) 1994; 33: 491-3
68. Karrar ZA. Vitamin D deficiency rickets in developing countries. Ann Trop Paediatr 1998; 18 Suppl.: S89-92
69. Agarwal KS, Mughal MZ, Upadhyay P, et al. The impact of atmospheric pollution on vitamin D status of infants and toddlers in Delhi, India. Arch Dis Child 2002; 87: 111-3
70. Marks R, Foley PA, Jolley D, et al. The effect of regular sunscreen use on vitamin D levels in an Australian population: results of a randomized controlled trial. Arch Dermatol 1995; 131: 415-21
71. Specker BL, Valanis B, Hertzberg V, et al. Sunshine exposure and serum 25-hydroxyvitamin D concentrations in exclusively breast-fed infants. J Pediatr 1985; 107: 372-6
72. Bhowmick SK, Johnson KR, Retting KR. Rickets caused by vitamin D deficiency in breast-fed infants in the southern United States [letter]. Am J Dis Child 1991; 145: 127-30
73. Clemens TL, Adams JS, Henderson SL, et al. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982; I: 74-6
74. Specker B. Vitamin D requirements during pregnancy. Am J Clin Nutr 2004; 80: 1740S-7S
75. Tylavsky FA, Ryder KA, Lyytikainen A, et al. Vitamin D, parathyroid hormone, and bone mass in adolescents. J Nutr 2005; 135: 2735S-8S
76. Dagnelie PC, Vergote FJ, Van Staveren WA, et al. High prevalence of rickets in infants on macrobiotic diets. Am J Clin Nutr 1990; 51: 202-8
77. Ford JA, McIntosh WB, Dunnigan MG. A possible relationship between high-extraction cereal and rickets and osteomalacia. Adv Exp Med Biol 1977; 81: 353-62
78. Daniels ED, Pettifor JM, Moodley GP. Serum osteocalcin has limited usefulness as a diagnostic marker for rickets. Eur J Pediatr 2000; 159: 730-3
79. Markestad T, Halvorsen S, Seeger Halvorsen K, et al. Plasma concentration of vitamin D metabolites before and during treatment of vitamin D deficiency rickets in children. Acta Pediatrica Scand 1984; 73: 225-31
80. Chesney R, Zimmerman J, Hamstra A, et al. Vitamin D metabolites concentration in vitamin D deficiency. Am J Dis Child 1981; 135: 1025-8
81. Vieth R, Walfish PG. How much vitamin D supplementation do adults require to ensure a serum 25(OH)D optimal for suppression of PTH [abstract]. J Bone Res 2000; 15 Suppl. 1: S231
82. Weaver C, Fleet JC. Vitamin D requirements: current and future. Am J Clin Nutr 2004; 80 (6 Suppl.): 1735S-9S
83. Kruse K. Pathophysiology of calcium metabolism in children with vitamin D-deficiency rickets. J Pediatr 1995; 126: 736-41
84. Stanbury SW, Taylor C, Lumb GA, et al. Formation of vitamin D metabolites following correction of human vitamin D deficiency: observation in patients with nutritional ostomalacia. Mineral Electrolyte Metab 1981; 5: 212-27
85. Kitanaka S, Takeyama K, Murayama A, et al. Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 1998; 338: 653-61
86. Fraser D, Kooh SW, Kind P, et al. Pathogenesis of hereditary vitamin D-dependent rickets: an inborn error of metabolism involving defective conversion of 25-hydroxyvitamin D to 1,25 hydroxy-vitamin D. N Engl J Med 1973; 289: 817-22
87. Delvin EE, Glorieux FH, Marie PJ, et al. Vitamin D dependency: replacement therapy with calcitriol. J Pediatr 1981; 99: 26-34
88. Malloy PJ, Pike JW, Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25 dihydroxyvitamin D-resistant rickets. Endocr Rev 1999; 20: 156-88
89. Liberman UA, Samuel R, Halabe A, et al. End-organ resistance to 1,25-dihydroxy cholecalciferol. Lancet 1980; I: 504-6
90. HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995; 11: 130-6
91. Ward LM. Renal phosphate-wasting disorders in childhood. Pediatr Endocrinol Rev 2005; 2 Suppl. 3: 342-50
92. Blydt-Hansen TD, Tenenhouse HS, Goodyer P. PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatr Nephrol 1999; 13: 607-11
93. Shih NR, Jo OD, Yanagawa N. Effects of PHEX anti-sense in human osteoblast cells. J Am Soc Nephrol 2002; 13: 394-9
94. Shimada T, Muto T, Hasegawa H, et al. FGF-23 is a novel regulator of mineral homeostasis with unique properties controlling vitamin D metabolism and phosphate reabsorption [abstract]. J Bone Miner Res 2002; 17 Suppl. 1: S425
95. Popovtzer MM. Tumor-induced hypophosphatemic osteomalacia (TIO): evidence for a phosphaturic cyclicAMP-independent action of tumor extract [abstract]. Clin Res 1981; 29: 418A
96. Rowe PS. The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 2004; 15 (5): 264-81
97. Saggese G, Baroncelli GI, Bertelloni S, et al. The effects of long-term growth hormone treatment on bone mineral density in children with GH deficiency: role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab 1996; 81: 3077-83
98. Yu X, White KE. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 2005; 16: 221-32
99. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001; 98: 6500-5
100. Rowe PS. Molecular biology of hypophosphataemic rickets and oncogenic osteomalacia. Hum Genet 1994; 94 (5): 457-67
101. Bergwitz C, Roslin NM, Tieder M, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006; 78: 179-92
102. Chesney R, Jones DP. Rickets due to renal tubular abnormalities. In: Glorieux FH, Pettifor JM, Juppner H. editors. Pediatric bone: biology and diseases. Amsterdam: Academic Press, 2003: 633-50
103. Clarke BL, Wynne AG, Wilson DM, et al. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 1995; 43 (4): 479-90
104. Scheinman SJ, Guay-Woodford LM, Thakker RV, et al. Genetic disorders of renal electrolyte transport. N Engl J Med 1999; 340: 1177-87
105. Thakker RV. Chloride channels cough up. Nat Genet 1997; 17: 125-7
106. Butani L, Kalia A. Idiopathic hypercalciuria in children: how valid are the existing diagnostic criteria? Pediatr Nephrol 2004; 19 (6): 577-82
107. Raja KA, Schurman S, D'Mello RG, et al. Responsiveness of hypercalciuria to thiazide in Dent's disease. J Am Soc Nephrol 2002; 13: 2938-44
108. Reusz GS, Dobos M, Tulassay T, et al. Hydrocholorothiazide treatment of children with hypercalciuria: effects and side-effects. Pediatr Nephrol 1993; 7: 699-702
109. Rodriguez-Soriano J, Vallo A. Renal tubular acidosis. Pediatr Nephrol 1990; 4: 268-75
110. Sanchez CP. Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. Pediatr Drugs 2003; 5 (11): 763-76
111. Ziolkowska H. Minimizing bone abnormalities in children with renal failure. Pediatr Drgus 2006; 8 (4): 205-22
112. Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 2002; 17 Suppl. 2: 21-4
113. Jono S, Shioi A, Ikari Y, et al. Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006; 24 (2): 176-81
114. Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21 (2): 151-9
115. Mactier RA, Van Stone J, Cox A, et al. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcaemia. Clin Nephrol 1987; 28: 222-6
116. Nolan CR, Qunibi WY. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens 2003 Jul; 12 (4): 373-9
117. Querfeld U. The therapeutic potential of novel phosphate binders. Pediatr Nephrol 2005; 20: 389-92
118. Cunningham J. New vitamin D analogues for osteodystrophy in chronic kidney disease. Pediatr Nephrol 2004; 19: 705-8
119. Robinson DM, Scott LJ. Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. Drugs 2005; 65: 559-76
120. Hokken-Koelega A, Mulder P, De Jong R, et al. Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Pediatr Nephrol 2000; 14 (7): 701-6
121. Whyte PW. Sclerosing bone dysplasias. In: Favus MJ, editor. Primer on metabolic bone diseases and disorders of mineral metabolism. 2nd ed. New York: Raven Press, 1993: 327-44
122. Balemans W, Van Wesenbeeck L, Van Hul W. A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int 2005; 77: 263-74
123. Kocher MS, Kasser JR. Osteopetrosis. Am J Orthop 2003; 32: 222-8
124. Tsuji Y, Ito S, Isoda T, et al. Successful nonmyeloablative cord blood transplantation for an infant with malignant infantile osteopetrosis. J Pediatr Hematol Oncol 2005; 27: 495-8
125. Janssens K, Vanhoenacker F, Bonduelle M, et al. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet 2006; 43: 1-11
126. Greenspan A, Azouz EM. Bone dysplasia series: melorheostosis: review and update. Can Assoc Radiol J 1999; 50: 324-30
127. Whyte PW. Hypophoshatasia. In: Favus MJ, editor. Primer on metabolic bone diseases and disorders of mineral metabolism. 2nd ed. New York: Raven Press, 1993: 288-90
128. Barcia JP, Strife CF, Langman CB. Infantile hypophosphatasia: treatment options to control hypercalcemia, hypercalciuria, and chronic bone demineralization. J Pediatr 1997; 130: 825-8
129. Coe JD, Murphy WA, Whyte MP. Management of femoral fractures and pseudofractures in adult hypophosphatasia. J Bone Joint Surg Am 1986; 68: 981-90
130. Whyte MP, Kurtzberg J, McAlister WH, et al. Marrow cell transplantation for infantile hypophosphatasia. J Bone Miner Res 2003; 18: 624-36
131. Girschick HJ, Seyberth HW, Huppertz HI. Treatment of childhood hypophosphatasia with nonsteroidal antiinflammatory drugs. Bone 1999; 25: 603-7
132. DiCaprio MR, Enneking WF. Fibrous dysplasia: pathophysiology, evaluation, and treatment. J Bone Joint Surg Am 2005; 87: 1848-64
133. Parekh SG, Donthineni-Rao R, Ricchetti E, et al. Fibrous dysplasia. J Am Acad Orthop Surg 2004; 12 (5): 305-13
134. Chapurlat RD, Hugueny P, Delmas PD, et al. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004; 35: 235-42
135. Yamamoto T. Clinical approach to clarifying the mechanism of abnormal bone metabolism in McCune Albright syndrome. J Bone Miner Metab 2006; 24 (1): 7-10
136. Hagenas L, Hertel T. Skeletal dysplasia, growth hormone treatment and body proportion: comparison with other syndromic and non-syndromic short children. Horm Res 2003; 60 Suppl. 3: 65-70
137. Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000; 21 (1): 23-39
138. Cundy T, Hegde M, Naot D, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002; 11: 2119-27
139. Cundy T, Wheadon L, King A. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 2004; 19: 703-11
140. Cundy T, Davidson J, Rutland MD, et al. Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 2005; 353: 918-23
141. Fitch N. Albright's hereditary osteodystrophy: a review. Am J Med Genet 1982; 11 (1): 11-29
142. Nakamoto J, Sandstrom A, Brickman A, et al. Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gsalpha gene mutation. Am J Med Genet 1998; 77 (4): 261-7
143. Charrow J, Poznanski A. The Jansen type of metaphyseal chondrodysplasia: confirmation of dominant inheritance and review of radiographic manifestations in the newborn and the adult. Am J Med Genet 1984; 18 (2): 321-7
144. Palenzuela L, Vives-Bauza C, Fernandez-Cadenas I, et al. Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. J Med Genet 2002; 39: E67
145. Whyte MP, Mills BG, Reinus WR, et al. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. J Bone Miner Res 2000; 15 (12): 2330-44
146. Ai M, Heeger S, Bartels CF, et al.; Osteoporosis-Pseudoglioma Collaborative Group. Clinical and molecular findings in osteoporosis- pseudoglioma syndrome. Am J Hum Genet 2005; 77 (5): 741-53
147. Levasseur R, Lacombe D, de Vernejoul MC. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 2005; 72: 207-14
148. Hartikka H, Makitie O, Mannikko M, et al. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 2005; 20: 783-9
149. Must A, Nixon PA, Pivarnik JM, et al. Evidence based physical activity for school-age youth. J Pediatr 2005; 146: 732-7
150. Lorentzon M, Mellstrom D. Association of amount of physical activity with cortical bone size and trabecular volumetric BMD in young adult men: the GOOD Study. J Bone Miner Res 2005; 20: 1936-43
151. Davies JH, Evans BA, Gregory JW. Bone mass acquisition in healthy children. Arch Dis Child 2005; 90: 373-8
152. Bonjour JP, Chevalley T, Ferrari S, et al. Decisions about increasing calcium intake in healthy children and adolescents [abstract]. Bone 2005; 36 Suppl. 1: S5
153. Institute of Medicine. Dietary reference intakes: calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press, 1997: 5-9
154. Bonjour JP, Chevalley T, Ammann P, et al. Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study. Lancet 2001; 358: 1208-12
155. Lanou AJ, Berkow SE, Barnard ND. Calcium, dairy products, and bone health in children and young adults: a reevaluation of the evidence. Pediatrics 2005; 115 (3): 736-43
156. Abrams SA, Griffin IJ, Hawthorne KM, et al. Vitamin D receptor Fok1 polymorphisms affect calcium absorption, kinetics, and bone mineralization rates during puberty. J Bone Miner Res 2005; 20: 945-53
157. Metabolism, mechanism of action and clinical applications. In: Favus M, editor. Primer on metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington, DC: American Society for Bone and Mineral Research, 2003: 129-37
158. De Luca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80 Suppl.: 1689S-96S
159. Gartner LM, Greer FR. Prevention of rickets and vitamin D deficiency: new guidelines for vitamin D intake. Pediatrics 2003; 111: 908-10
160. Department of Health. Nutrition and bone health: with particular reference to calcium and vitamin D [report on health and social subjects 49]. London: HMSO, 1998
161. National Institute for Clinical Excellence. Antenatal care: routine care for healthy pregnant women. National Collaborating Centre for Women's and Childrens Health. London: Royal College of Obstetricians and Gynaecologists, 2003 Oct
162. Delvin EE, Glorieux FH, Marie PJ, et al. Vitamin D dependency: replacement therapy with calcitriol. J Pediatr 1981; 99: 26-34
163. Marx SJ, Spiegel AM, Brown EM, et al. A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 1978; 47 (6): 1303-10
164. Marx SJ, Bliziotes MM, Nanes M. Analysis of the relation between alopecia and resistance to 1,25-dihydroxyvitamin D. Clin Endocrinol (Oxf) 1986; 25 (4): 373-81
165. Takeda E, Kuroda Y, Saijo T, et al. 1α-hydroxyvitamin D3 treatment of three patients with 1,25 dihydroxyvitamin D-receptor-defect rickets and allopecia. Pediatrics 1987; 80: 97-101
166. Chan GM, Mileur L, Hansen JW. Calcium and phosphorus requirements in bone mineralization of preterm infants. J Pediatr 1988; 113: 225-9
167. Markowitz MM. Rickets associated with hypophosphatemia. In: Peskovitz OH, Engster EA, editors. Pediatric endocrinology: mechanisms, manifestations and management. Philadelphia (PA): Lippincott Williams and Wilkins, 2004: 655-70
168. Russell RGG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporosis Int 1999; 9 Suppl. 1: S66-80
169. Papapoulos SE. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Kesey J, editors. Osteoporosis. New York: Academic Press, 1996: 1209-34
170. Glorieux FH, Bishop H, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-9
171. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86: 356-64
172. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004; 363: 1427-31
173. Ward LM, Denker AE, Porras A, et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 2005; 90: 4051-6
174. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20 (5): 758-63
175. Rauch F, Glorieux FH. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long? Ann Med 2005; 37: 295-302
176. Seikaly MG, Kopanati S, Salhab N, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 2005; 25: 786-91
177. Vyskocil V, Pikner R, Kutilek S. Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 2005; 72: 416-23
178. Cho TJ, Choi IH, Chung CY, et al. Efficacy of oral alendronate in children with osteogenesis imperfecta. J Pediatr Orthop 2005; 25: 607-12
179. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006; 21: 132-40
180. Forin V, Arabi A, Guigonis V, et al. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study. Joint Bone Spine 2005; 72: 313-8
181. Zeitlin L, Rauch F, Travers R, et al. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. Bone 2006; 38 (1): 13-20
182. DiMeglio LA, Ford L, McClintock C, et al. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004; 35 (5): 1038-45
183. Hawker GA, Ridout R, Harris VA, et al. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil 2005; 86: 284-8
184. Acott PD, Wong JA, Lang BA, et al. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 2005; 20: 368-73
185. Cimaz R, Gattorno M, Sormani MP, et al. Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. J Rheumatol 2002; 29: 1786-92
186. Henderson RC, Lark RK, Kecskemethy HH, et al. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002; 141: 644-51
187. Allington N, Vivegnis D, Gerard P. Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta Orthop Belg 2005; 71: 91-7
188. Golden NH, Iglesias EA, Jacobson MS, et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005; 90: 3179-85
189. Millonig G, Graziadei IW, Eichler D, et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 2005; 11: 960-6
190. El-Husseini AA, El-Agroudy AE, El-Sayed MF, et al. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 2004; 8: 357-61
191. Kerdudo C, Aerts I, Fattet S, et al. Hypercalcemia and childhood cancer: a 7-year experience. J Pediatr Hematol Oncol 2005; 27: 23-7
192. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21: 389-406
193. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7
194. Tarassoff P, Csermak K. A vascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003; 61: 1238-9
195. Land C, Rauch F, Glorieux FH. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 2006; 21: 374-9
196. Munns CF, Rauch F, Mier RJ, et al. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004; 35: 231-4
197. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349: 457-63
198. Zucchini S, Scarano E, Baldazzi L, et al. Final height in a patient with Laron syndrome after long-term therapy with rh IGF-I and short-term therapy with LHRH-analogue and oxandrolone during puberty. J Endocrinol Invest 2005; 28: 274-9
199. Niu T, Rosen CJ. The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene 2005; 361: 38-56
200. Inzerillo AM, Zaidi M, Huang CL. Calcitonin: physiological actions and clinical applications. J Pediatr Endocrinol Metab 2004; 17: 931-40
201. Nishioka T, Kurayama H, Yasuda T, et al. Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis. J Pediatr 1991; 118: 703-7
202. Chesnut 3rd CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 2000; 109 (4): 267-76
203. Drobac S, Rubin K, Rogol AD, et al. A workshop on pubertal hormone replacement options in the United States. J Pediatr Endocrinol Metab 2006; 19 (1): 55-64
204. Kiess W, Conway G, Ritzen M, et al. Induction of puberty in the hypogonadal gril: practices and attitudes of pediatric endocrinologists in Europe. Horm Res 2002; 57 (1-2): 66-71
205. MacGillivray MH. Induction of puberty in hypogonadal children. J Pediatr Endocrinol Metab 2004; 17 Suppl. 4: 1277-87
206. Hogler W, Briody J, Moore B, et al. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy x-ray absorptiometry. J Clin Endocrinol Metab 2004; 89: 193-9
207. Grinspoon S, Miller K, Coyle C, et al. The severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab 1999; 84 (6): 2049-55
208. Karlsson MK, Weigall SJ, Duan Y, et al. Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women recovered from anorexia nervosa. J Clin Endocrinol Metab 2000; 85 (9): 3177-82
209. Grinspoon S, Thomas L, Miller K, et al. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002; 87: 2883-91
210. Couto-Silva AC, Trivin C, Adan L, et al. Management of boys with short stature and delayed puberty. J Pediatr Endocrinol Metab 2005; 18: 807-13
211. Antoniazzi F, Zamboni G, Bertoldo F, et al. Bone development during GH and GnRH analog treatment. Eur J Endocrinol 2004; 151 Suppl. 1: S47-54
212. Boot AM, Engels MAMJ, Boerma GJM, et al. Changes in bone mineral density, body composition and lipid metabolism during growth hormone treatment in children with GH-deficiency. J Clin Endocrinol Metab 1997; 82: 2423-8
213. Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res 1975; 7: 488-91
214. Saggese G, Baroncelli GI, Bertelloni S, et al. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism and bone density. J Pediatr 1995; 127: 395-402
215. Noda H, Onishi H, Saitoh K, et al. Growth hormone therapy may increase fracture risk in a pubertal patient with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2002; 15: 217-8
216. Marini JC, Hopkins E, Glorieux FH, et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res 2003; 18: 237-43
217. Boot AM, Nauta J, de Jong MCJW, et al. Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with or without growth hormone treatment. Clin Endocrinol (Oxf) 1998; 49: 665-72
218. Franceschini N, Joy MS, Kshirsagar A. Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism. Expert Opin Investig Drugs 2003; 12: 1413-21
219. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87: 2060-6
220. Morony S, Warmington K, Adamu S, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005; 146 (8): 3235-43
221. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703